Get the Stockscreener App
2.60
6.56%
0.16
After Hours:
2.59
-0.01
-0.38%
Cabaletta Bio Inc Stock (CABA) Latest News
Does Cabaletta Bio Inc (CABA) offer a good opportunity for investors? - SETE News
Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Sold by Jennison Associates LLC - MarketBeat
Cabaletta Bio Inc (CABA) Stock: A Value Analysis - The News Heater
Cabaletta Bio Inc (CABA) requires closer examination - US Post News
Market Highlights: Cabaletta Bio Inc (CABA) Ends on a High Note at 2.39 - The Dwinnex
Cabaletta Bio to Present at Guggenheim’s SMID Cap Biotech Conference - MSN
Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference - The Manila Times
Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference - GlobeNewswire Inc.
Cabaletta Bio Advances Autoimmune Therapy, Sets Strategic Goals for 2025 - MSN
Cabaletta Bio, Inc. (NASDAQ:CABA) Holdings Decreased by JPMorgan Chase & Co. - Defense World
JPMorgan Chase & Co. Has $1.32 Million Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Analysts Set Expectations for Cabaletta Bio FY2025 Earnings - Defense World
Brokers Issue Forecasts for Cabaletta Bio FY2025 Earnings - MarketBeat
Barclays PLC Buys 19,891 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio Discloses Unaudited Cash and Cash Equivalents of $164 Million as of December 31, 2024 - Defense World
HC Wainwright Reaffirms “Buy” Rating for Cabaletta Bio (NASDAQ:CABA) - Defense World
Cabaletta Bio (NASDAQ:CABA) Earns "Buy" Rating from HC Wainwright - MarketBeat
Brokerages Set Cabaletta Bio, Inc. (NASDAQ:CABA) PT at $24.38 - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Cabaletta Bio stock maintain buy rating on trial progress By Investing.com - Investing.com Canada
Cabaletta Bio's (CABA) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Cabaletta Bio stock maintain buy rating on trial progress - Investing.com
Cabaletta Bio Advances Clinical Trials with Lonza Partnership - TipRanks
Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025 - The Manila Times
A Look At The Behavior Of Hut 8 Corp (HUT) Stock - Stocks Register
Cabaletta Bio: Finding Optimism In Dire Straits (NASDAQ:CABA) - Seeking Alpha
Barclays PLC Has $288,000 Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Looking Into Cabaletta Bio's Recent Short Interest - Benzinga
Geode Capital Management LLC Raises Stock Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Jane Street Group LLC Lowers Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Short Interest in Cabaletta Bio, Inc. (NASDAQ:CABA) Rises By 38.2% - MarketBeat
State Street Corp Sells 1,109,678 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Sold by State Street Corp - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Stock Rating Lowered by Evercore ISI - Defense World
Cabaletta Bio's SWOT analysis: autoimmune CAR-T stock faces challenges, opportunities By Investing.com - Investing.com South Africa
Cabaletta Bio's SWOT analysis: autoimmune CAR-T stock faces challenges, opportunities - Investing.com
Cabaletta Bio (NASDAQ:CABA) Downgraded by Evercore ISI to "Inline" - MarketBeat
Wells Fargo Downgrades Cabaletta Bio (CABA) - MSN
Charles Schwab Investment Management Inc. Raises Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday - Benzinga
Cabaletta Bio (NASDAQ:CABA) Downgraded to Equal Weight Rating by Wells Fargo & Company - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio's SWOT analysis: CAR-T pioneer's stock faces pivotal moment - Investing.com
Cabaletta Bio, Inc.'s (NASDAQ:CABA) latest 25% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance
Is Cabaletta Bio (NASDAQ:CABA) In A Good Position To Invest In Growth? - Simply Wall St
Point72 Asset Management L.P. Makes New $3.15 Million Investment in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Jennison Associates LLC Reduces Stake in Cabaletta Bio Inc - GuruFocus.com
PRUDENTIAL FINANCIAL INC's Strategic Acquisition of Cabaletta Bi - GuruFocus.com
Walleye Capital LLC Acquires 212,025 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):